Lake Forest Regenesis Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A clinic can document a thoughtful evaluation process without demonstrating how much weight its patients lose. That distinction is central to Lake Forest Regenesis, an in-person practice in Lake Forest, Illinois, advertising GLP-1-based medical weight management. Its public materials describe two 90-minute appointments, blood testing and ongoing monitoring. Those are meaningful details about the proposed service, but they are not clinical outcome measurements, independent verification of pharmacy quality or evidence that a particular patient will receive a particular medication.

This review examines public documentation consulted October 19, 2026, separating the clinic’s stated offerings from the broader evidence for treatment. Lake Forest Regenesis identifies semaglutide and tirzepatide as possible options when clinically appropriate, including conditional discussion of compounded preparations. It does not publish an identifiable GLP-1 program price in the consulted materials. The prominently documented $119 monthly membership belongs to separate primary care—not weight management. For prospective patients, the strongest evidence is about the evaluation pathway; the largest unanswered questions concern the actual prescription, dispensing arrangements and financial terms.

At a glance

Documented service: The clinic advertises in-person GLP-1-based weight management, potentially including semaglutide or tirzepatide after an appropriate medical evaluation.
Sources: [7] [10]
Initial evaluation: The advertised process includes a 90-minute initial consultation with blood drawn, followed by a separate 90-minute results-review appointment.
Sources: [7]
Clinical lead: The practice identifies Allana Bush, FNP-C, as its lead medical provider; her credentials and claimed experience were not independently verified for this review.
Sources: [12]
Payment distinction: Services are self-pay and the clinic does not bill insurance. Its $119/month primary-care membership excludes specialty programs such as medical weight loss.
Sources: [10] [5]
Compounded-product disclosure: The medication pages acknowledge that compounded preparations are not FDA approved; the clinic’s pharmacy-registration claims do not establish product approval.
Sources: [9] [11] [1]

Start with the evidence the clinic actually provides

Lake Forest Regenesis’s terms identify the business as Lake Forest Regenesis Medical Center PLLC. Its GLP-1 page describes care for men and women in Lake Forest, Chicago’s North Shore and Lake County. The terms say all services are delivered in person after an appropriate medical evaluation, with suitability determined by the provider. This supports describing it as a local clinical practice offering medical weight management, rather than a nationwide medication-shipping service.

The practice names Allana Bush, FNP-C, as its lead medical provider and attributes more than 20 years of healthcare experience to her, spanning primary care, metabolic health and other areas. FNP-C identifies a family nurse practitioner credential, not a physician designation. These are provider-published descriptions, not independently verified licensing or experience findings. The distinction matters because a detailed professional biography and a verified credential check answer different questions.

The documentation establishes what the clinic says it offers, not how consistently those services are delivered or what outcomes follow. Its materials explicitly state that no specific amount or rate of weight loss is guaranteed. Our guide to what public provider documents can prove explains this boundary: service descriptions can support a practical account of enrollment and care, while treatment effectiveness at a particular practice requires a different kind of evidence.

What the public documentation establishes
Topic	Documented position	Remaining question
Care setting	In-person services in Lake Forest, Illinois	How appointments fit an individual’s travel and availability
Initial assessment	Two 90-minute visits, with blood drawn at the first	Consultation prices and laboratory turnaround
Medication options	Semaglutide- or tirzepatide-based therapy when appropriate	Exact product, formulation, presentation and dispensing pharmacy
Ongoing care	Monitoring of progress, tolerance and health	Visit frequency and GLP-1 support response time
Payment	Self-pay; primary care is a separate membership	Complete GLP-1 charges and cancellation or refund terms

Sources: [10] [12] [7] [6]

Two long appointments are a process commitment, not an outcome

The most specific part of the advertised GLP-1 pathway is its opening assessment. The first visit is a 90-minute consultation with Allana covering health history, current medications, previous weight-loss efforts, symptoms and personal goals. Blood is drawn during that visit. Once results are available, a second 90-minute appointment reviews the laboratory findings and other health information to determine whether GLP-1-based treatment may be appropriate. Neither appointment description promises a prescription.

This sequence gives prospective patients more to evaluate than a general promise of personalized care. It identifies who conducts the visits, when blood collection occurs and how results enter the decision. However, the consulted documentation does not identify the laboratory panel, turnaround time or interval between appointments. It also does not establish when treatment would begin after a favorable decision. Two lengthy visits should not be mistaken for a guaranteed start date or a defined treatment package.

The clinic says no referral is required and patients may schedule directly. Its terms add an important administrative qualification: submitting a website booking request does not confirm an appointment. Confirmation occurs when the office contacts the patient with a date and time. Before arranging time away from work or traveling, a prospective patient should therefore obtain confirmation and ask for the prices of both appointments and any blood testing, rather than treating a submitted request as a completed reservation.

Sources: [7] [5] [10]

The medication name is only the beginning of product identification

Lake Forest Regenesis says treatment may include semaglutide- or tirzepatide-based therapy when clinically appropriate, alongside medical evaluation, nutritional and lifestyle guidance, progress monitoring and provider oversight. Its individual medication pages describe the usual administration as a once-weekly injection under the skin. These descriptions establish the treatment categories being discussed; they do not identify the exact prescription, presentation, concentration or quantity that a particular patient would receive.

The medication pages separately discuss compounded semaglutide and compounded tirzepatide. For each, the clinic says that, when prescribed, the preparation comes from an FDA-registered compounding pharmacy and is not FDA approved. Elsewhere, it describes obtaining medications from compounding or specialty pharmacies selected for quality and dosing accuracy. That selection language is a provider claim. The consulted materials do not name the dispensing pharmacies or independently substantiate their registration, testing or quality-control practices.

References to Wegovy, Ozempic, Zepbound and Mounjaro in explanatory comparisons should not be read as confirmation that those brands are dispensed. A useful prepayment question is: What exact product would be prescribed, and which pharmacy would dispense it? Our discussion of approved medicines and compounded preparations explains why an ingredient name, a pharmacy’s regulatory status and approval of a finished product are separate evidence questions. The clinic’s conditional wording leaves the individual product decision unresolved.

Sources: [7] [9] [11] [5] [1]

Clinical trials do not measure this clinic’s performance

The broader clinical evidence for semaglutide and tirzepatide should not be confused with evidence about Lake Forest Regenesis. STEP 1 studied subcutaneous semaglutide in adults with obesity, or overweight with a weight-related condition, without diabetes. SURMOUNT-1 studied subcutaneous tirzepatide in a similarly defined population excluding diabetes. Neither trial evaluated this clinic, its assessment process, its pharmacy arrangements or any compounded preparation it might prescribe. Trial findings cannot establish the practice’s own success rate.

For readers reviewing numerical marketing claims, the key task is matching a claim to the actual research: population, duration, route, studied product, comparator and tolerability all matter. Sponsor funding also belongs in that appraisal. Our guide to reading STEP 1 provides a focused example. Neither a favorable drug trial nor a provider’s long consultation establishes that a different preparation, another route or an individual patient will reproduce a study’s average result.

The compounded-product question adds a separate regulatory boundary. FDA states that compounded preparations are not approved and do not undergo its premarket review for safety, effectiveness and quality. Nonapproval alone does not prove clinical inequivalence, nor does it validate or condemn this clinic. FDA recommends compounded drugs for patients whose medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Pharmacy registration is not a substitute for product approval.

Sources: [3] [4] [1]

Eligibility and monitoring are described, but the schedule is not

The clinic directs its GLP-1 program toward adults who have struggled to lose or maintain weight through nutrition and exercise alone, or who have weight-related health concerns. It expects participation in ongoing medical follow-up, lifestyle changes and long-term weight management. The consulted program materials do not publish numerical BMI thresholds or a more specific minimum age. Website rules allowing adults to request their own care, and separate primary-care age provisions, should not be repurposed as GLP-1 eligibility criteria.

The provider also documents clinical screening boundaries. Its general GLP-1 page says pregnancy, breastfeeding, certain histories, contraindications, medication interactions or other concerns may prevent a recommendation. Its medication pages state exclusions involving personal or family history of medullary thyroid carcinoma, MEN 2 and pregnancy; the tirzepatide page also calls for careful review of pancreatitis, gallbladder disease or kidney problems. The tirzepatide page also warns that oral birth control may be less effective for about four weeks after starting treatment and after each dose increase; patients using oral contraception should discuss this with their prescriber. These are the clinic’s published screening statements, not an individualized eligibility determination or a complete substitute for clinical assessment.

For continuing care, the clinic says follow-up examines weight progress, appetite, tolerance, side effects and overall health. Plans may be adjusted, paused or discontinued as circumstances change. Treatment length is individualized, and maintenance may involve continued medication or another adjustment. What remains undocumented is the visit cadence and GLP-1-specific support response time. The distinction between scheduled monitoring and on-demand help is worth clarifying; clinical follow-up involves more than renewal, especially when a patient needs advice between visits.

Sources: [7] [9] [11] [10] [2]

The $119 membership does not establish a GLP-1 price

Lake Forest Regenesis’s terms say it does not bill insurance and that services are self-pay, with payment options explained when booking. No identifiable price for the GLP-1 program, either medication or the two initial consultations appears in the consulted documentation. This is a concrete limitation, not evidence that treatment is unusually expensive or inexpensive. Without a written quote, readers cannot determine the first payment, recurring cost, billing interval or whether laboratory work and medication are bundled.

The published $119/month figure is for Direct Primary Care. That membership covers primary-care sick visits, preventive care, physicals and ongoing health concerns. Medications, laboratory tests, imaging and specialty programs such as medical weight loss or hormone therapy are separate. Members are offered contact with Allana by email, text, portal message or phone, with a response within one business day. Neither that response promise nor the membership’s visit coverage should automatically be extended to the separate GLP-1 service.

The terms also say prices and programs can change without notice, while any third-party financing depends on the outside provider’s terms and approval. The consulted materials do not establish GLP-1 automatic renewal, minimum commitment, prepayment, cancellation deadlines or refunds. Patients should request an itemized written proposal and the applicable cancellation terms before payment. The absence of published conditions does not establish that there is no commitment, and stopping treatment clinically does not establish entitlement to a refund.

Sources: [10] [5]

Local access is clear; medication handoff is less clear

The practice lists its location as 1025 W. Everett Road, Suite 2, Lake Forest, in the same building as Lake Forest Acute Care Center, at Everett and Waukegan roads. Suite 2 is on the lower level and accessible by stairs or elevator. Those details support practical visit planning. They do not establish a relationship with the other facility beyond the shared building, and the in-person terms do not support describing the program as available through interstate remote care.

Published contact information includes 224-436-8006 and info@lakeforestregenesis.com. Office hours are Monday through Wednesday and Friday, 8 a.m.–6 p.m., and Saturday, 9 a.m.–1 p.m.; Thursday and Sunday are closed. These are office hours, not a documented around-the-clock clinical response promise. Prospective patients should ask which contact route handles medication questions, what happens outside office hours and whether language assistance is available, since the consulted materials do not confirm Spanish-language care or interpretation.

The pharmacy-to-patient handoff is not described with comparable precision. The public documentation does not establish pickup versus shipment, delivery charges, dispatch or arrival timelines, storage arrangements or the responsible contact for a delivery problem. These questions should be settled with the clinic and dispensing pharmacy before medication is sent. As general regulatory guidance, FDA explicitly advises not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy to resolve the concern.

Sources: [10] [8] [1]

Keep lifestyle support and optional services in separate evidence categories

Lake Forest Regenesis presents medication as part of a broader approach rather than a replacement for nutrition, physical activity and sustainable habits. That is a documented program principle, but it does not specify how much counseling is delivered, by whom or at what additional cost. NIDDK similarly describes weight-management medication as accompanying healthy eating and activity. Agreement on that principle does not independently demonstrate the intensity or effectiveness of this clinic’s lifestyle support.

The clinic also discusses Emsculpt NEO as a possible body-composition complement, while explicitly stating that it is not a weight-loss or obesity treatment and does not replace medical weight management. Its Emsculpt page calls a consultation recommended but not required, whereas the general terms require an appropriate medical evaluation for services. The documentation does not explain whether this reflects a distinction between a formal consultation and another evaluation. That ambiguity should not be imported into the clearly described GLP-1 assessment pathway.

Taken together, these distinctions provide a practical checklist for a consultation: identify the prescription and pharmacy, request the full financial terms, establish the monitoring schedule and separate optional services from the core plan. Ask what evidence supports each proposed component rather than treating all clinic offerings as one proven package. The public pages document a proposed care structure; they do not provide a provider-specific outcome dataset showing average weight change, discontinuation, adverse events or long-term maintenance.

Sources: [7] [6] [13] [10] [2]

Questions & answers

Does Lake Forest Regenesis actually advertise GLP-1 treatment?

Yes. Its medical weight-management page identifies semaglutide- or tirzepatide-based therapy as possible options when clinically appropriate, with evaluation and ongoing oversight. That confirms an advertised service, not a guaranteed prescription. The terms specify in-person care, and the documented service area centers on Lake Forest, Chicago’s North Shore and Lake County. The materials do not establish nationwide telehealth access.

Sources: [7] [10]

What happens before a medication decision?

The advertised pathway starts with a 90-minute consultation with Allana and blood collection. A second 90-minute visit, after results return, reviews the findings and determines whether GLP-1-based treatment may be appropriate. No referral is required. Ask about appointment charges, laboratory costs and timing before booking; the public materials do not specify those amounts or turnaround times, and a website request is not itself appointment confirmation.

Sources: [7] [5] [10]

Does the $119 monthly membership include weight-loss treatment?

No. The documented $119/month membership covers Direct Primary Care, while medical weight loss is a separate specialty program. Medication, laboratory tests and imaging are also separate from that membership. The consulted pages do not establish the GLP-1 program’s price or inclusions. Request a written quote distinguishing evaluation, follow-up, testing, medication and any supplies rather than using the primary-care figure as a treatment estimate.

Sources: [5] [10]

Will I receive an FDA-approved brand or a compounded preparation?

The public documentation does not settle that for an individual patient. It conditionally discusses compounded semaglutide and tirzepatide, acknowledges that these preparations are not FDA approved and says the provider will explain available options. Informational brand comparisons do not confirm dispensing of those brands. Ask for the exact product and pharmacy, and why that option is being proposed, before making a medication-related payment.

Sources: [9] [11] [5] [1]

How often are follow-ups, and how quickly can I get help?

The clinic describes regular monitoring of weight, appetite, tolerance, side effects and general health, but does not publish a specific GLP-1 follow-up interval or response deadline in the consulted materials. The one-business-day response statement belongs to primary-care membership. Ask separately about scheduled GLP-1 appointments, between-visit questions, after-hours concerns and any extra charges. The published office schedule includes Saturday morning hours but excludes Thursdays and Sundays.

Sources: [7] [5] [8]

Can I cancel treatment or obtain a refund?

The clinic says a treatment plan may be adjusted, paused or discontinued for clinical reasons. That is not a financial cancellation or refund policy. The consulted materials do not establish GLP-1 renewal rules, minimum commitments, notice requirements or refund eligibility. Before paying, obtain the applicable terms for appointments, medication orders and continuing services, including what happens financially if the evaluation does not lead to a prescription.

Sources: [7] [10]

Our assessment

Lake Forest Regenesis provides a relatively concrete account of its initial GLP-1 assessment: in-person care, a named nurse practitioner, blood collection and two lengthy visits before a suitability decision. It also acknowledges compounded-product nonapproval and does not guarantee a particular weight-loss result. Those disclosures make the proposed service easier to understand, but they do not establish provider-specific effectiveness or independently verify pharmacy quality. The central unresolved issues are practical and material: exact product, dispensing pharmacy, complete price, follow-up access and cancellation terms. For someone considering this local practice, the next useful step is obtaining those details in writing—not projecting clinical-trial averages onto the clinic or treating its separate $119 primary-care membership as a GLP-1 offer.

Visit Lake Forest Regenesis’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Lake Forest Regenesis Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the evidence the clinic actually provides

02Two long appointments are a process commitment, not an outcome

03The medication name is only the beginning of product identification

04Clinical trials do not measure this clinic’s performance

05Eligibility and monitoring are described, but the schedule is not

06The $119 membership does not establish a GLP-1 price

07Local access is clear; medication handoff is less clear

08Keep lifestyle support and optional services in separate evidence categories